Shionogi & Co., Ltd. (OTCMKTS:SGIOF – Get Free Report) is projected to announce its resultson Monday, August 3rd. Analysts expect Shionogi & Co., Ltd. to announce earnings of $0.2861 per share and revenue of $977.7730 million for the quarter.
Shionogi & Co., Ltd. Stock Performance
Shares of OTCMKTS:SGIOF opened at $17.45 on Monday. The stock has a fifty day simple moving average of $17.83 and a two-hundred day simple moving average of $19.57. Shionogi & Co., Ltd. has a 12-month low of $14.25 and a 12-month high of $26.00.
About Shionogi & Co., Ltd.
Shionogi & Co, Ltd. is a research-driven pharmaceutical company headquartered in Osaka, Japan, with origins dating back to 1878. The company concentrates on the discovery, development and sale of prescription medicines in key therapeutic areas, including infectious diseases, pain management, cardiovascular and metabolic disorders, central nervous system disorders and oncology. Shionogi’s mission emphasizes addressing unmet medical needs, particularly in the field of antimicrobial resistance, where it has developed both small-molecule antibiotics and novel treatment approaches.
The firm’s product portfolio comprises marketed therapies such as Cresemba (isavuconazole) for invasive fungal infections, and Fetroja (cefiderocol), a siderophore cephalosporin antibiotic for multidrug-resistant Gram-negative infections.
Read More
- Five stocks we like better than Shionogi & Co., Ltd.
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
